成人午夜又粗又硬又长_鲁一鲁AV2019在线_欧美深深色噜噜狠狠yyy_www.91色.com_色影音先锋av资源网_特级做A爰片久久毛片A片喷水_99精品无人区乱码1区2区3区_国产人妻久久精品一区_欧美午夜精品久久久久久浪潮_av免费无码天堂在线_蜜桃色欲AV久久无码精品软件_日美一级毛片_久久久久久久久性潮_国产乱对白精彩_日韩精品免费一区二区_亚洲欧美精品在线_无码国产69精品久久久久_开心五月综合激情综合五月_干一夜综合_亚洲中文有码字幕日本

    在過去幾年中，日本安斯泰來公司不斷加強其疫苗研究領域的實力，研發并在日本上市了流感疫苗新產品。現在公司決定繼續擴大自己在該領域的影響力。安斯泰來公司和瑞士的ClearPath公司簽訂合作協議，在未來將建立新的疫苗研發公司以開發新的疫苗產品。目前安斯泰來公司旗下只有RSV Corporation一家類似性質的公司。RSV Corporation公司目前已經從瑞士生物技術公司Mymetics公司獲得了呼吸道合胞體病毒疫苗，該疫苗目前尚處于二期驗證試驗，一旦實驗完成，安斯泰來公司將重新評估這一疫苗的價值并開始著手進一步的研究和商業化進程。據了解安斯泰來公司與ClearPath公司的合作也是公司在8個月前著手進行研發業務重組的重要部分。
    而ClearPath公司也將在協議中扮演重要角色，公司將致力于獲得各種疫苗研究領域的早期研究成果并通過重新評估后將這些疫苗候選者商業化。
    詳細英文報道：
    Over the past few years, Astellas Pharma has strengthened its vaccine business by codeveloping a flu vaccine, licensing a cytomegalovirus candidate and introducing a new product in Japan. This week, Astellas once again looked beyond its walls to grow the unit, inking an alliance to build a portfolio of biotechs developing infectious disease vaccines.
    The partnership sees Astellas team up with ClearPath, a Switzerland-based company that helps develop early-stage drugs. Together, the companies plan to create a portfolio of biotechs to develop vaccine assets for Astellas but so far have only set up one such business--RSV Corporation. The company has licensed a respiratory syncytial virus (RSV) vaccine candidate from Swiss biotech Mymetics in a deal worth up to $82 million in upfront and post-proof-of-concept milestone payments.
    Astellas has committed to funding the vaccine until completion of the Phase IIb proof-of-concept trial. Once the vaccine has reached this stage, Astellas will reevaluate the project and may exercise its exclusive right to acquire RSV Corp. or further develop and commercialize the candidate. In an attempt to reach this point quickly and affordably, Astellas has assembled a mix of third-party support. Mymetics will continue to help with preclinical work and former Wyeth vaccine chief Dr. George Siber will lead RSV's development team.
    ClearPath will also play an active role in development. The company is made up of former executives from CROs, biopharma businesses, regulators and funding groups who now collectively help firms advance early-stage candidates to proof-of-concept. "Together we are harnessing our collective resources to accelerate development of this promising, early-stage asset and will replicate this scalable, outcome-driven model across future portfolio companies," ClearPath Chairman Chuck Finn said in a press release.
    Astellas' embrace of the ClearPath model comes 8 months after it revealed plans to shake up its R&D operation. The rejig saw Astellas shutter facilities and outline a different strategy for "unique and challenging" early-stage candidates. The approach--called the "Ex. (External/Expedite/Exploratory) Track"--was designed to flexibly use internal and external resources to more efficiently bring drugs to proof-of-concept. RSV looks like an early example of this model.